ORSIRO Sirolimus Eluting Coronary Stent System
Biotronik AG · Decision date Feb 22, 2019
What did the FDA approve?
FDA approved the Orsiro Sirolimus Eluting Coronary Stent System from Biotronik AG on February 22, 2019. The approval record states the device is indicated for improving coronary luminal diameter in patients with symptomatic heart disease, stable angina, unstable angina, non-ST elevation myocardial infarction, or documented silent ischemia due to atherosclerotic lesions in native coronary arteries.
The stated indication includes patients with diabetes mellitus and specifies a reference vessel diameter of 2.25 mm to 4.0 mm and a lesion length of less than 36 mm. The record does not contain a supplement type or supplement reason, and no clinical effectiveness data or trial information is provided in the source fields.
FDA approval order statement
Approval of the Orsiro Sirolimus Eluting Coronary Stent System. This device is indicated for improving coronary luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, non-ST elevation myocardial infarction or documented silent ischemia due to atherosclerotic lesions in the native coronary arteries with a reference vessel diameter of 2.25 mm to 4.0 mm and a lesion length of < 36 mm.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 22, 2019
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P170030
- Regulatory pathway
- Premarket approval application
- Applicant
- Biotronik AG
- Product code
- NIQ
- Decision code
- APPR
- Decision date
- Feb 22, 2019
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Coronary drug-eluting stent.
- Applicant
- Biotronik AG
- Product code
- NIQ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P170030 received
Application receipt date recorded by FDA.
P170030 · FDA decision
APPR
P170030/S066 · Related supplement
ORSIRO Sirolimus Eluting Coronary Stent System
Timeline entries are records held by MedtechLedger for P170030. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170030
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ORSIRO Sirolimus Eluting Coronary Stent SystemP170030/S066 | Biotronik AG | PMA supplement | Sep 24, 2026 | FDA |
Explore the linked device profile
Other records with product code NIQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular | PMA supplement | Oct 16, 2026 | FDA | |
| Abbott Vascular | PMA supplement | Oct 1, 2026 | FDA | |
| Medtronic Vascular | PMA approval | Apr 28, 2017 | FDA | |
| Abbott Vascular | PMA approval | Nov 1, 2011 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik AG
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Ackerstrasse 6, Bülach, 8180
Sources and methodology
- Original FDA record: P170030
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



